BMJ Open Respir Res. 2025 Oct 13;12(1):e002899. doi: 10.1136/bmjresp-2024-002899. ABSTRACT BACKGROUND: Lung cancer, a leading cause of cancer deaths, is […]
BMJ Open. 2025 Oct 13;15(10):e096314. doi: 10.1136/bmjopen-2024-096314. ABSTRACT OBJECTIVES: To explore the longitudinal experience of taking part in a physiotherapy-led
Vaccine. 2025 Oct 12:127771. doi: 10.1016/j.vaccine.2025.127771. Online ahead of print. ABSTRACT BACKGROUND: Patients with autoimmune inflammatory rheumatic diseases (AIRDs) are
Clin Chim Acta. 2025 Oct 11:120651. doi: 10.1016/j.cca.2025.120651. Online ahead of print. ABSTRACT Inflammatory bowel disease (IBD), which includes Crohn’s
RMD Open. 2025 Oct 13;11(4):e006149. doi: 10.1136/rmdopen-2025-006149. ABSTRACT Music therapy is recognised as a complementary or alternative therapy for osteoarthritis
Fr J Urol. 2025 Oct 11:103003. doi: 10.1016/j.fjurol.2025.103003. Online ahead of print. ABSTRACT INTRODUCTION: Urinary oxalate (UOx) excretion is a
Ann Hepatol. 2025 Oct 11:102140. doi: 10.1016/j.aohep.2025.102140. Online ahead of print. ABSTRACT INTRODUCTION AND OBJECTIVES: Pruritus is a frequent and
Aging Dis. 2025 Sep 17. doi: 10.14336/AD.2025.0830. Online ahead of print. ABSTRACT Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)
J Bras Nefrol. 2025 Oct-Dec;47(4):e20250092. doi: 10.1590/2175-8239-JBN-2025-0092en. ABSTRACT Given the relevance of renal involvement in systemic lupus erythematosus (SLE) and
Osteoporos Int. 2025 Oct 13. doi: 10.1007/s00198-025-07722-8. Online ahead of print. ABSTRACT The impact of romosozumab on the bone mineral
Rheumatol Int. 2025 Oct 13;45(11):249. doi: 10.1007/s00296-025-05997-y. ABSTRACT To examine the central sensitization and its determinants in systemic lupus erythematosus
Rheumatol Int. 2025 Oct 13;45(11):248. doi: 10.1007/s00296-025-05965-6. NO ABSTRACT PMID:41081910 | DOI:10.1007/s00296-025-05965-6
Clin Rheumatol. 2025 Oct 13. doi: 10.1007/s10067-025-07747-8. Online ahead of print. NO ABSTRACT PMID:41082107 | DOI:10.1007/s10067-025-07747-8
Drugs Real World Outcomes. 2025 Oct 13. doi: 10.1007/s40801-025-00514-w. Online ahead of print. ABSTRACT BACKGROUND: Older adults are under-represented in
Eur Geriatr Med. 2025 Oct 13. doi: 10.1007/s41999-025-01327-4. Online ahead of print. ABSTRACT AIM: To examine the association of muscle
Asian Pac J Allergy Immunol. 2025 Oct 13. doi: 10.12932/AP-090625-2090. Online ahead of print. ABSTRACT BACKGROUND: Asthma is a heterogeneous
JAMA Intern Med. 2025 Oct 13. doi: 10.1001/jamainternmed.2025.5201. Online ahead of print. NO ABSTRACT PMID:41082225 | DOI:10.1001/jamainternmed.2025.5201
Acta Paediatr. 2025 Oct 12. doi: 10.1111/apa.70329. Online ahead of print. ABSTRACT AIM: During the COVID-19 pandemic, Sweden chose a
Expert Rev Clin Immunol. 2025 Oct 13. doi: 10.1080/1744666X.2025.2575448. Online ahead of print. ABSTRACT INTRODUCTION: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD)
J Thorac Imaging. 2025 Oct 13. doi: 10.1097/RTI.0000000000000855. Online ahead of print. ABSTRACT PURPOSE: Patients with connective tissue diseases (CTDs)
Expert Rev Clin Immunol. 2025 Oct 13. doi: 10.1080/1744666X.2025.2575355. Online ahead of print. ABSTRACT INTRODUCTION: Difficult-to-treat psoriatic arthritis (D2T-PsA) is
ACR Open Rheumatol. 2025 Oct;7(10):e70110. doi: 10.1002/acr2.70110. ABSTRACT OBJECTIVE: Kawasaki disease (KD) is an acute systemic vasculitis predominantly affecting coronary
Rheumatology (Oxford). 2025 Oct 13:keaf532. doi: 10.1093/rheumatology/keaf532. Online ahead of print. ABSTRACT OBJECTIVES: Few recent epidemiological data are available on
Rheumatology (Oxford). 2025 Oct 13:keaf487. doi: 10.1093/rheumatology/keaf487. Online ahead of print. ABSTRACT OBJECTIVES: Psoriatic arthritis (PsA) increases cardiovascular disease risk.
Rheumatology (Oxford). 2025 Oct 13:keaf534. doi: 10.1093/rheumatology/keaf534. Online ahead of print. NO ABSTRACT PMID:41081306 | DOI:10.1093/rheumatology/keaf534
J Allergy Clin Immunol. 2025 Jul 16:S0091-6749(25)00623-2. doi: 10.1016/j.jaci.2025.05.028. Online ahead of print. ABSTRACT BACKGROUND: Omalizumab, a therapeutic mAb targeting
Osteoporos Int. 2025 Oct 13. doi: 10.1007/s00198-025-07706-8. Online ahead of print. ABSTRACT This first-of-its-kind survey reveals deep gaps in awareness,
